PFIZER INC — Director's Dealing 2023

Feb 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2023-02-25

Reporting Person: McDermott Michael (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-25	Common Stock	M	14178.0000	$22.8900	Acquired	93099.0000	Direct
2023-02-25	Common Stock	F	2839.0000	$41.7500	Disposed	90260.0000	Direct
2023-02-25	Common Stock	F	6305.0000	$43.4400	Disposed	83955.0000	Direct
2023-02-27	Common Stock	F	3081.0000	$40.7800	Disposed	80874.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-25	Stock Appreciation Rights	$22.8900	M	14178.0000	Disposed	2023-02-25	Common Stock (14178.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: Price is the closing price of Pfizer common stock on February 24, 2023.

F4: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F5: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F6: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.